1. Motzer, et al. A multicenter, phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC). American Clinical Society of Oncology (ASCO) Annual Meeting. June 2015, Chicago, USA.
7. Siegel, R et al. Cancer Statistics. CA Cancer J Clin. 2014;64:9–29.
8. Motzer et al. Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol. 2015; 32: 1-5.
9. Knox, et al. Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC). American Clinical Society of Oncology (ASCO) Annual Meeting. June 2015, Chicago, USA.